Malignant Diseases Flashcards

1
Q

Define Wilm’s Tumour.

A

Wilms tumour originates from embryonal renal tissue and is the most common renal tumour of childhood.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

When do Wilm’s tumours present?

A

Over 80% of patients present before 5 years of age and it is very rarely seen after 10 years of age.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How do Wilm’s tumours present?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the investigations of Wilm’s Tumours?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the management of Wilm’s tumours?

A
  • In the UK, children receive initial chemotherapy
  • Followed by delayed nephrectomy
  • After which the tumour is staged histologically and subsequent treatment is planned according to the surgical and pathological findings.
  • Radiotherapy is restricted to those with more advanced disease.
  • Initial nephrectomy followed by chemotherapy is an approach taken in some countries.
  • Around 5% of patients have bilateral disease at diagnosis, and their management is directed to preserve as much renal function as possible.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the prognosis of Wilm’s Tumours?

A

Prognosis is good, with more than 80% of all patients cured. Cure rate for patients with metastatic disease at presentation (~15%) is over 60%, but relapse carries a poor prognosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How to brain tumours differ in children to adults?

A
  • In children, almost always primary rather than metastatic
  • 60% are infratentorial (located below tentorium cerebelli)
  • Most common solid tumour in children
  • Leading cause of childhood cancer death in UK
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the types of paediatric brain tumours? Briefly describe them.

A
o Astrocytoma (40%): varies from (low grade) to highly malignant (high grade, *glioblastoma multiforme* ).
o Medulloblastoma (20%): arise in midline of the posterior fossa, 20% have spinal metastases at diagnosis
o Ependymoma (8%): most common site is IVth ventricle but may arise anywhere in CSF spaces. 10% are slow growing low grade but the remainder present as aggressive tumours requiring complete resection and radiotherapy for cure.
o Brainstemglioma(6%):poorprognosis
o Craniopharyngioma (4%): developmental tumour arising from the squamous remnant of Rathke pouch. Not truly malignant but locally invasive and grows slowly in suprasellar region
o Atypical teratoid/rhabdoid tumour
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What do the clinical features of brain tumours depend on?

A
  • Age
  • Site of tumour
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How do brain tumours present in all ages?

A

o Persistent or recurrent vomiting
o Problems with balance, coordination or walking
o Behavioural change
o Abnormal eye movements
o Seizures, without fever
o Abnormal head position: wry neck, head tilt or persistent stiff neck

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How do brain tumours present in children/adolescents?

A

o Persistent or recurrent headache
o Blurred or double vision
o Lethargy
o Deteriorating school performance
o Delayed or arrested puberty, slow growth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How do brain tumours present in infants?

A

o Developmental delay

o Progressive increase in head circumference, separation of sutures, bulging fontanella

o Lethargy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How do brain tumours from different sites present?

A

o Supratentorial(cortex)

▪ Seizures

▪ Hemiplegia

▪ Focal neurological signs

o Midline

▪ Visual field loss: bitemporal hemianopia

▪ Pituitary failure: growth failure, diabetes insipidus, weight gain

o Cerebellar and 4th ventricle

▪ Truncal ataxia
▪ Coordination difficulties

▪ Abnormal eye movements

o Brainstem
▪ Cranial nerve defects

▪ Pyramidal tract signs
▪ Cerebrallar signs: ataxia

▪ Often no raised ICP

• Spinal tumours can present with back pain, peripheral weakness of arms or legs or bladder/bowel dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the investigations for brain tumours?

A
  • Brain tumours are best characterized on MRI scan.
  • Magnetic resonance spectroscopy can be used to examine the biological activity of a tumour and aid radiological diagnosis.
  • Some tumour types can metastasize within the CSF and a lumbar puncture is therefore required for complete staging of the disease.
    • Lumbar puncture must not be performed without neurosurgical advice if there is any suspicion of raised intracranial pressure.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

14 yr old

Aggressive behaviour at school, headaches, seizures

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

10 yr old complaining of headaches, nausea, poor growth, struggling to see board at school.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

3 yr old vomiting in the morning, unsteady on his feet, new onset convergent squint.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

4 yr old. Refuses to walk, unable to climb, squint, facial asymmetry and drooling.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

How should we manage brain tumours?

A
  • Surgery is usually the first treatment and is aimed at:
    • treating hydrocephalus
    • providing a tissue diagnosis
    • attempting maximum resection.
  • In some cases the anatomical position of the tumour means biopsy is not safe,
    • e.g. tumours in the brainstem and optic pathway.
  • Even tumours which are histologically ‘benign’ can threaten survival.
  • The use of radiotherapy and/or chemotherapy varies with tumour type and the age of the patient.

In the acute phase, neurorehabilitation including physiotherapy, occupational therapy, speech and language therapy may be required to support optimal recovery. Survivors living with disability, growth, endocrine, neuropsychological, and educational problems require complex care management into adulthood.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

How common is leukaemia in children?

A

Leukaemia most common type of cancer in childhood in developed world

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What are the types of of leukaemia?

A

ALL accounts for 80% of leukaemia in children.

o Others: acute myeloid leukaemia, acute non-lymphocytic leukaemia

o CML and other myeloproliferative disorders are rare

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What are the clinical features of ALL?

A

Peak age of ALL presentation is 2-5 years

Symptoms occur due to disseminated disease and systemic illness from infiltration of bone marrow or other organs with leukaemic blast cells

Presents insidiously over several weeks usually

General: malaise, anorexia

Bone marrow infiltration

o Bonepain
o Anaemia → pallor, lethargy
o Neutropenia → infection
o Thrombocytopenia → bruising, petechiae, nose bleeds

• Reticulo-endothelial infiltration

o Hepatosplenomegaly

o Lymphadenopathy (superior mediastinal obstruction) – uncommon

• Other organ infiltration

o CNS→headaches, vomiting, nerve palsies

o Testes → testicular enlargement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What are the investigations for ALL?

A

• FBC will be abnormal

o Usually with a low Hb, thrombocytopaenia and evidence of circulating leukaemic blast cells

Bone marrow biopsy - essential to confirm diagnosis

Clotting screen

o 10% of patients with acute leukaemia have DIC at the time of diagnosis

Lumbar puncture can reveal disease in the CSF

CXR can reveal a mediastinal mass (characteristic of T-cell disease)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

How are ALL and AML classified?

A

Both ALL and AML are classified by morphology. Immunological phenotyping further subclassifies ALL; the common B-cell (75%) and T-cell (15%) subtypes are the most frequent. Prognosis and some aspects of clinical presentation vary according to different subtypes, and treatment intensity is adjusted accordingly.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

How do we think about managing ALL?

A
  • Consider factors contributing to prognosis
  • Supportive therapy
  • Before starting treatment, anaemia may need to be corrected using blood transfusions
  • Consider CNS disease/involvement
  • Second phase: After remission: Consolidation and maintenance therapy
  • Treat Relapse, refractory, or residual disease
26
Q

What factors contribute to prognosis of ALL?

A
27
Q

What supportive therapy do we give for ALL?

A

o Sufficient fluid intake to guarantee urine output of 100 mL/hour

o Allopurinol or rasburicase to prevent tumour lysis syndrome

o Bleeding patients or low platelet count may require transfusions

o Prophylactic antibiotics, antifungals, and antivirals

o Prophylactic use of haematopoietic growth factors e.g. CSF (filgrastim) in those at risk of febrile neutropenia

o Norethisterone can be given to female patients to suppress periods during therapy and periods of thrombocytopenia

28
Q

What is the treatment for newly diagnosed: no CNS disease ALL?

A

o Induction chemotherapy
Standard induction includes prednisolone, vincristine, anthracyclines (e.g. doxorubicin, daunorubicin) and/or L-asparaginase)
Dexrazone (prevent cardiotoxicity from doxorubicin)
Rituximab (if CD20+ ALL)
Tyrosine kinase inhibitors (e.g. imatinib) - for Philadelphia chromosome-positive patients

29
Q

How should you manage ALL with CNS involvement?

A

o Cytotoxic drugs penetrate poorly into the CNS
o Standard induction therapy with intensified intrathecal chemotherapy is, therefore, required to prevent CNS relapse
o Currently recommended regimens consist of frequent intrathecal methotrexate alone or with cytarabine and hydrocortisone (‘triple’), and consolidation therapy containing systemic treatment with high-dose cytarabine (HDAC) or high-dose methotrexate (HDM) to ensure good blood-brain penetration

30
Q

What is the second phase of ALL treatment after induction of remission?

A

• The second phase of treatment after induction of remission consists of consolidation and maintenance therapy

o Remission occurs when leukaemic blasts are eradicated and normal marrow function is restored

o Current induction regimens achieve remission rates of 95%
o Continuing chemotherapy of moderate-high intensity is usually continued for a relatively long time (up to 3 years)

31
Q

How should an ALL relapse, refractory or residual disease be treated?

A

High-dose chemotherapy, with or without total body irradiation followed by bone marrow transplantation, is used as an alternative to conventional chemotherapy after a relapse

32
Q

Define lymphoma.

A

Malignancies of the cells of the immune system

33
Q

Describe the epidemiology of lymphoma?

A

o Childhood = Non-Hodgkin lymphoma

o Adolescence = Hodgkin lymphoma

34
Q

What are the clinical features of Hodgkin’s lymphoma?

A

▪ Painless lymphadenopathy (often in the neck)
▪ Lymph nodes are larger and firmer than benign lymphadenopathy

▪ Lymph nodes may cause airway or SVC obstruction
▪ Reasonably long clinical history (months)
▪ Systemic symptoms (B symptoms) are UNCOMMON

35
Q

What are the investigations of Hodgkin’s lymphoma?

A

▪ Lymph node biopsy

▪ Radiological assessment of extranodal sites

▪ Bone marrow biopsy

36
Q

What is the management of Hodgkin’s lymphoma?

A
  • Combination chemotherapy (ABVD: Adriamycin (Doxorubicin), bleomycin, vinblastine and dacarbazine) with/without radiotherapy
  • Favourable disease: two cycles of ABVD followed by low dose radiation
  • Unfavourable disease:
    • four cycles of ABVD followed by medium radiation OR
    • BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisolone), followed by two cycles of ABVD and radiotherapy
  • Primary refractory or relapse disease:
    • High-dose chemotherapy and autologous stem cell transplantation (ASCT)
    • Brentuximab vedotin (anti CD30) can be prescribe if ASCT fails or is ASCT is unsuitable
    • Nivolumab and Pembrolizumab (both block PD-1) are last line
  • PET scanning is used to monitor treatment response
37
Q

What are the cure rates of Hodgkin’s lymphoma?

A

80%

38
Q

What is present in both NHL and ALL?

A

T-cell malignancy: The mediastinal mass can cause superior vena cava obstruction. This presents with dyspnoea, facial swelling and flushing, venous distention in the neck, and distended veins in the upper chest and arms

39
Q

How do B cell malignancies present in NHL?

A

o B cell malignancies present more commonly as NHL, with localised lymph node disease

o Abdominal disease presents with pain from intestinal obstruction, a palpable mass or even intussusception

40
Q

What are the investigations for NHL?

A
  • Biopsy
  • CT or MRI
  • Examination of BM and CSF
41
Q

What is the management of NHL?

A
  • Multiagent chemotherapy
  • Survival rates of 80% are achieved in both B and T cell disease
42
Q

What is Burkitt’s lymphoma? Where does it most commonly occur?

A

o Type of B-cell NHL
o Three variants
o Endemic variant most commonly occurs in children living in malaria endemic regions - it is the most common childhood cancer in Africa

43
Q

What infection is associated with Burkitt’s lymphoma? What are the clinical features? Hows it managed?

A

o EBV is found in nearly all patients with Burkitt lymphoma

▪ NOTE: chronic malaria is thought to reduce resistance to EBV infection

o The disease usually involves the jaw or other facial bones
o In the Western world, cases are sporadic and are associated with EBV infection
o Immunodeficiency-associated Burkitt’s lymphoma is usually associated with HIV infection or occurs in patients on immunosuppression o Treated with multiagent chemotherapy

44
Q

Define neuroblastoma.

A

A malignant tumour arising from the embryological neural crest tissue in the adrenal medulla and sympathetic nervous system

Most commonly arises from the adrenal glands but can form anywhere that SNS tissue is present e.g. paraspinal sympathetic ganglia in chest and abdomen

Spontaneous regression sometimes occurs in young infants

45
Q

How malignant is a neuroblastoma?

A

It is a biologically unusual tumour in that spontaneous regression sometimes occurs in very young infants and there is a spectrum of disease from the benign (ganglioneuroma) to the highly malignant (neuroblastoma).

46
Q

At what age are neuroblastoma common?

A

Under age of 5 yrs

47
Q

What are the clinical features of neuroblastoma?

A
  • Pallor
  • Weight loss
  • Abdominal mass (present in most children with neuroblastoma)
    • o Mass crosses midline
      o Tumour can be anywhere along the sympathetic chain from neck to pelvis
      o The abdominal primary is usually of adrenal origin but at presentation the tumour mass is often large and complex enveloping major vessels and lymph nodes
  • Hepatomegaly
  • Bone pain
  • Limp
  • Rare symptoms: paraplegia, cervical lymphadenopathy, proptosis, periorbital bruising, skin nodules
  • Paravertebral tumours can cause spinal cord compression
48
Q

What. are the investigations of neuroblastoma?

A

CT/MRI

High urine catecholamine metabolites (VMA and HVA)

Biopsy

Bone marrow sampling

MIBG scan

o MIBG is a molecule that is taken up by neuroblastoma cells, so if the MIBG is labelled with radioactive iodine, it can be used to identify areas of high uptake

o It can also be used as a form of targeted radiotherapy

Most children presenting > 1 year of age present with advance disease and have a POOR prognosis

Note: amplification of the MYCN oncogene predicts aggressive behaviour of the tumour

49
Q

What is the management of neuroblastoma? What are cure rates?

A

Low risk disease (localised primaries without metastatic disease, in some infants may resolve spontaneously)

o Observation (serial ultrasounds every 3-6 weeks) +/- surgery

o Chemotherapy if progresses post-surgery

Intermediate risk (Metastatic disease)

o Chemotherapy AND surgery

  • Carboplatin, etoposide, cyclophosphamide, and doxorubicin for 4-8 cycles

o Radiotherapy is unsuccessful

High risk (Aggressive and metastatic disease)

o Radiotherapy

  • High dose carboplatin, etoposide, cyclophosphamide, and doxorubicin for 5-6 cycles

o Surgery
o Autologous bone marrow transplant

o Radiotherapy
o Immunotherapy with Dinutuximab
o Isotretinoin

Cure rates for children with metastatic disease is around 40%

50
Q

When and in who are bone tumours common? What are the types of tumours?

A

Uncommon before puberty

Osteosarcoma is MORE COMMON than Ewing sarcoma

Ewing sarcoma is seen more often in younger children

Bone tumours are more common in MALES

51
Q

What are the clinical features of bone tumours?

A

Limbs are the most common site

Persistent localised bone pain

o Indication for an X-ray

• Most patients are otherwise well

52
Q

What are the investigations of bone tumours?

A

• Plain X-ray

o Shows bone destruction and periosteal new bone formation

o In Ewing sarcoma, there is often a substantial soft tissue mass

MRI

Bone scan

Chest CT (to look for lung metastases)

Bone marrow sampling (exclude bone marrow involvement)

53
Q

What is the management of bone tumours?

A
  • In both tumours, treatment involves the use of combination chemotherapy given before surgery.
  • Whenever possible, amputation is avoided by using en bloc resection of tumours with endoprosthetic resection
  • In Ewing sarcoma, radiotherapy is also used in the management of local disease, especially when surgical resection is impossible or incomplete, e.g. in the pelvis or axial skeleton.
54
Q

Define retinoblastoma

A

Malignant tumour fo the retinal cells

55
Q

How often does retinoblastoma cause visual impairment in children?

A

5%

56
Q

What causes retinoblastoma?

A

Can be unilateral or bilateral

All bilateral tumours are hereditary, approx. 20% of unilateral cases are hereditary

Affects retinoblastoma susceptibility gene on chromosome 13

Dominant inheritance with incomplete penetrance

Most children present within first 3 years of life

Children from families with hereditary form of disease should be screened regularly from

birth

57
Q

What are the clinical features of retinoblastoma?

A

White pupillary reflex replaces normal red reflex (usually seen incidentally)

Squint

58
Q

What are the investigations of retinoblastoma?

A

MRI

Examination under anaesthetic

Tumours are often multifocal

59
Q

What is the management of retinoblastoma?

A
  • Average age of diagnosis: 18 months
  • In propriety, goals of treatment: Save life, save eye, save vision
  • Frequent eye examinations under anaesthesia to assess the response to treatment
  • Gross vitreous seeding present (tumor cells floating within the vitreous cavity)
    • o 1st LINE: Enucleation (surgical removal of the eye without resection of the lids or extraocular muscles
    • o Infiltration of the iris, ciliary body or sclera: Adjuvant chemotherapy: carboplatin, etoposide, and vincristine
  • Minimal or no vitreous seeding present
    • 1st LINE: systemic chemotherapy (carboplatin, vincristine, etoposide)
    • PLUS: focal therapy (cryotherapy or laser therapy)
  • Family history of retinoblastoma/detected at birth
    • Usually treated by laser alone
    • Followed up with an examination under anaesthesia every month for at least 1 year
  • Vitreous seeding after chemotherapy and/or focal therapy
    • 1st LINE: external beam radiotherapy
60
Q

What is the prognosis of retinoblastoma?

A

Most patients are cured (90%)

However, many will be visually impaired

Significant risk of second malignancy (especially sarcoma) among survivors of hereditary retinoblastoma